GV1001 0.56mg

DRUG2 trials

Sponsors

GemVax & Kael

Conditions

Mild to Moderate Alzheimer's DiseaseProgressive Supranuclear Palsy

Phase 2

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

CompletedNCT05189210

GemVax & KaelMild to Moderate Alzheimer's Disease

Start: 2022-10-05End: 2025-04-16Updated: 2025-09-04

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

CompletedNCT05819658

GemVax & KaelProgressive Supranuclear Palsy

Start: 2023-06-14End: 2024-10-11Updated: 2026-02-10